

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

D2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/20	A1	(11) International Publication Number: WO 97/46230 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/US97/04538 (22) International Filing Date: 19 March 1997 (19.03.97) (30) Priority Data: 08/659,845 7 June 1996 (07.06.96) US 08/736,562 28 August 1996 (28.08.96) US (71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; P.O. Box 7365, Madison, WI 53707-7365 (US). (72) Inventors: COOK, Mark, E.; 15 Kewaunee Court, Madison, WI 53705 (US); PARIZA, Michael, W.; 7102 Valhalla Trail, Madison, WI 53719 (US). (74) Agent: KRYSHAK, Thad; Quarles & Brady, 411 East Wisconsin Avenue, Milwaukee, WI 53202-4497 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
(54) Title: METHOD FOR MAINTAINING AN EXISTING LEVEL OF BODY FAT AND/OR BODY WEIGHT		
(57) Abstract		
A method of maintaining an existing level of body fat or body weight in a human which comprises administering to a human desiring to maintain that existing level a safe and effective amount of conjugated linoleic acid (CLA) to maintain that level.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

METHOD FOR MAINTAINING
AN EXISTING LEVEL OF BODY FAT AND/OR BODY WEIGHT

Field of the Invention

The present invention generally relates to human nutrition. More particularly, it relates to a method of treating humans to maintain an existing level of body fat
5 and/or body weight.

Background of the Invention

There are a significant number of people, who are happy with their existing body weights and levels of body fat, but who do not want their weight or levels of body fat to
10 increase. In addition, thousands of people annually go on diets to lose body fat or weight. Unfortunately, most of those that are successful cannot maintain the lower levels of body fat and/or body weight which they have achieved.

There is a need for a method of maintaining an existing
15 level of body fat and/or body weight in a human.

Brief Summary of the Invention

It is an object of the present invention to disclose a method of maintaining an existing level of body fat and/or body weight in a human.

20 We have discovered that an existing level of body fat and/or body weight in a human can be maintained by administering to the human a safe and effective amount of an active form of a conjugated linoleic acid, such as 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, an ester
25 thereof, a non-toxic salt thereof, and mixtures thereof.

The terms "conjugated linoleic acids" and "CLA" as used herein are intended to include 9,11-octadecadienoic acid, 10,12-octadecadienoic acid and their active derivatives, such as non-toxic salts and esters, and mixtures thereof.

30 The present method can be used by ex-dieters to maintain the lower level of body fat and/or body weight they have achieved or by persons who wish to increase their fat intake without increasing their level of body fat and/or body weight.

-2-

It will be apparent to those skilled in the art that the forementioned objects and other advantages may be achieved by the practice of the present invention.

Description of the Preferred Embodiment

5 The present method comprises administering to the human desirous of maintaining his or her existing level of body fat and/or body weight a safe and effective amount of an active form of a conjugated linoleic acid, which is selected from a conjugated linoleic acid, such as 9,11-octadecadienoic acid
10 and 10,12-octadecadienoic acid, an ester thereof, a non-toxic salt thereof, and mixtures thereof.

 The existing level of the human's body fat and/or body weight can be determined by a variety of methods. The body weight of a person can be obtained simply by weighing the
15 person. One method of determining body fat simply comprises doing a "pinch test" at the waist, chest, thighs and other body parts. Another more sophisticated method, which is commonly used for athletes, involves completely submerging the person in liquid and calculating the body weight under water.

20 The amount of the CLA to be administered normally is an amount which is equal to about 1% to about 30% of the fat in the human's diet. If the CLA is taken in pharmaceutical dosage form the dose will normally be about 100 mg. to 20,000 mg. per day of CLA in the form of the free acids. Since the
25 CLA is a natural food ingredient and relatively non-toxic, the amount which can be consumed is not critical as long as it is enough to be effective and it is not contraindicated because of the human's health.

 The practice of the present invention is further
30 illustrated by the examples which follow:

Example 1

SYNTHESIS OF CONJUGATED LINOLEIC ACIDS (CLA) FROM LINOLEIC ACID AND SAFFLOWER OIL

35 Propylene glycol (1000 g) and 500 g potassium hydroxide (KOH) are put into a 4-neck round bottom flask (5000 ml). The flask is equipped with a mechanical stirrer, a thermometer, a

-3-

reflux condenser, and a nitrogen inlet. (The nitrogen introduced in first run through two oxygen traps).

Nitrogen is bubbled into the propylene glycol and KOH mixture for 20 minutes and the temperature is then raised to
5 180°C.

1000 g of linoleic acid, corn oil, or safflower oil is then introduced into the flask. The mixture is heated at 180° C under an inert atmosphere for 2.5 hours.

The reaction mixture is cooled to ambient conditions and
10 600 ml HCl is added to the mixture which is stirred for 15 minutes. The pH of the mixture is adjusted to pH 3. Next, 200 ml of water is added into the mixture and stirred for 5 minutes. The mixture is transferred into a 5 L separatory funnel and extracted three times with 500-ml portions of hexane.

15 The aqueous layer is drained and the combined hexane solution extracted with four 250-ml portions of 5% NaCl solution.

The hexane is washed 3 times with water. The hexane is transferred to a flask and the moisture in the hexane removed
20 with anhydrous sodium sulfate (Na_2SO_4). The hexane is filtered through Whatman paper into a clean 1000 ml round bottom flask and the hexane removed under vacuum with a rotoevaporator to obtain the CLA. The CLA is stored in a dark bottle under argon at -80° C until time of use.

25 This method can be modified so as to utilize only food-grade reagents and solvents as listed in *Food Chemicals Codex*, fourth edition, Institute of Medicine, National Academy Press, 1996.

The active forms of CLA include, in addition to the free
30 acids, the non-toxic salts thereof, the active esters thereof, such as triglycerides, and mixtures thereof.

The free conjugated linoleic acids (CLA) have been previously isolated from fried meats and described as anticarcinogens by Y. L. Ha, N. K. Grimm and M. W. Pariza, in
35 *Carcinogenesis*, Vol. 8, No. 12, pp. 1881-1887 (1987). Since then, they have been found in some processed cheese products. Y. L. Ha, N. K. Grimm and M. W. Pariza, in *J. Agric. Food Chem.*, Vol. 37, No. 1, pp. 75-81 (1987). The free acid

-4-

forms of the CLA may be prepared by isomerizing linoleic acid. The non-toxic salts of the free acids may be made by reacting the free acids with a non-toxic base.

One method of synthesizing CLA is described in Example 1. However, CLA may also be prepared from linoleic acid by the action of a linoleic acid isomerase from a harmless microorganism, such as the Rumen bacterium Butyrivibrio fibrisolvens. Harmless microorganisms in the intestinal tracts of rats and other monogastric animals may also convert linoleic acid to CLA (S. F. Chin, J. M. Storkson, W. Liu, K. Allbright and M. W. Pariza, 1994, J. Nutr. 124; 694-701.

The CLA obtained by the practice of the described methods of preparation contains one or more of the 9,11-octadecadienoic acids and/or 10,12-octadecadienoic acids and active isomers thereof. It may be free or bound chemically through ester linkages. The CLA is heat stable and can be used as is, or dried and powdered. The CLA is readily converted into a non-toxic salt, such as the sodium or potassium salt, by reacting chemically equivalent amounts of the free acid with an alkali hydroxide at a pH of about 8 to 9. CLA also can be esterified to glycerol to form mono-, di-, and triglycerides.

Theoretically, 8 possible geometric isomers of 9,11- and 10,12-octadecadienoic acid (c9, c11; c9,t11; t9,c11; t9,2t11; c10,c12; c10,t12; t10,c12 and t10,t12) would form from the isomerization of c9,c12-octadecadienoic acid. As a result of the isomerization, only four isomers (c9,c11; c9,t11; t10,c12; and c10,c12) would be expected. However, of the four isomers, c9,t11- and t10,c12- isomers are predominantly produced during the autoxidation or alkali-isomerization of c9,c12-linoleic acid due to the co-planar characteristics of 5 carbon atoms around a conjugated double-bond and spatial conflict of the resonance radical. The remaining two c,c-isomers are minor contributors.

The relatively higher distribution of the t,t-isomers of 9,11- or 10,12-octadecadienoic acid apparently results from the further stabilization of c9,t11- or t10,c12- geometric isomers, which is thermodynamically preferred, during an extended processing time or long aging period. Additionally the

-5-

t,t-isomer of 9,11- or 10,12-octadecadienoic acid that was predominantly formed during the isomerization of linoleic acid geometrical isomers (t9,t12-, c9,t12- and t9,c12-octadecadienoic acid) may influence the final ratio of the isomers or the final CLA content in the samples.

Linoleic acid geometrical isomers also influence the distribution of minor contributors (c,c-isomers of 9,11- and 10,12-, t9,c11- and c11,t12-octadecadienoic acids). The 11,13-isomer might be produced as a minor product from c9,c12-octadecadienoic acid or from its isomeric forms during processing.

The exact amount of CLA to be administered to a human to maintain a level of body fat, of course, can depend upon the food the human consumes, the form of CLA employed, and the route of administration. It also can depend upon the isomer ratios. However, generally the amount administered will be the equivalent of about 1% to about 30% of the weight of the fat in the human's diet.

The CLA can be administered in food or as pharmaceutical compositions containing the CLA as a free acid; a salt thereof; an ester thereof, such as a triglyceride; or mixtures thereof.

The amount of CLA to be administered can be expressed as the amount of CLA based on the total calories consumed daily by the patient e.g. 0.03 to 3 gram CLA per 100 calories. Alternatively, the amount of CLA can be expressed as a percentage of the lipid or fat in the food, such as 0.3% to 100% of the food lipid, or as an amount of CLA per gram of food lipid, such as 3 to 1000 mg. CLA per gram of lipid consumed by the patient.

Generally, the amount of CLA to be administered in pharmaceutical dosage form will normally be about 100 mg. to about 20,000 mg. of CLA in the form of the free acids per day. However, the upper limit of the amount to be employed is not critical because CLA is relatively non-toxic.

The CLA and its non-toxic derivatives, such as the non-toxic salts, in addition to being added to an animal's food can be administered in the form of pharmaceutical compositions,

-6-

such as tablets, wafer, capsules, solutions or emulsions to the humans.

The preferred pharmaceutical compositions of CLA contain the non-toxic sodium, potassium or calcium salt of CLA in combination with a pharmaceutical diluent. When the compositions are solutions or suspensions intended for oral administration, the diluent will be one or more liquid diluents. When the product is a tablet or capsule, other conventional diluents, such as lactose, can be employed.

Examples 2 to 4 describe representative foods containing added CLA.

Example 2

A liquid preparation for parenteral administration to humans contains emulsified fat particles of about 0.33-0.5 μm in diameter. In addition, the emulsions can contain Water for Injection USP as a diluent, egg phosphatides (1-2%) as an emulsifying agent and glycerin (2-3%) to adjust toxicity. These emulsions can be infused intravenously to patients requiring parenteral nutrition. A preparation for use in the present invention would contain the same ingredients plus 0.5 mg/gm to 10 mg/gm of CLA or alternatively, 0.3% to 100% CLA based on the food lipid or 0.03 gram to 3 gram per 100 calorie serving. For such parenteral foods the CLA usually should be present in the form of the triglycerides.

Example 3

A dietetic margarine for use in the present invention is a semi-solid or solid vegetable oil-based margarine which, in addition to the usual ingredients, contains CLA. Such a margarine will contain about 0.25 mg/gram to about 800 mg/gm of CLA or about 0.003 gram to 9 gm CLA per 100 calorie serving.

Example 4

A low residue liquid enteral dietetic product useful as a high-protein, vitamin and mineral supplement contains added CLA. The amount of CLA present can be about 0.05% to about 5% by weight of the product or about 0.3% to about 100% of the lipid present or about 0.03 to 3 gram CLA per 100 calories.

- 7 -

One serving (140 calories) of a representative formula can contain the following:

	Protein (egg white solids)	7.5 g
	Fat (CLA)	0.1 g
5	Carbohydrate (sucrose, hydrolyzed corn starch)	27.3g
	Water	1.9 g
	Vitamins and Minerals	(RDA amounts)

It will be readily apparent to those skilled in the art
10 that many other foods, including those described in U.S. Patent
Nos. 4,282,265 and 5,470,839, can be prepared by adding CLA to
the food or by replacing some of the fat in the food with CLA.

The following examples illustrate the practice of the method of the present invention.

15 Example 5

The level of body fat of a 168 pound (4.75 kg), healthy human male, age 40 was determined using the "pinch test" on his waist, thighs and upper arms and his weight was determined by weighing on a scale. He then was administered four capsules (2400 mg of CLA as the fatty acids) daily and permitted to consume an unrestricted diet. After eight weeks it was determined that his weight (4.66 kg) and body fat level had stabilized at lower levels on an unrestricted diet. CLA consumption was stopped for one week while food consumption was unrestricted. After the one week period he was weighed and it was found that three pounds (84.75 g) of body weight had been gained. The administration of CLA at the original dosage was resumed for seven weeks whereupon the body weight and body fat levels returned to the lower levels previously reached after the initial eight weeks of administration of CLA. In the past, he had normally gained weight and body fat on an unrestricted diet. Similar results were obtained in several other humans.

Example 6

A healthy 210 pound (5.93 kg) male human, age 53, consumed 1200 mg CLA per day for three weeks. During this time his appetite was somewhat diminished. He then increased his CLA

-8-

intake to 2400 mg per day and noted a further decrease in appetite. Throughout this time he did not lose body weight but noted a decrease in body fat as evidenced by the "pinch" test.

Example 7

5 A healthy 176 pound (4.97 kg) female, age 53, consumed 1200 mg CLA per day. Within three weeks she had lost four pounds (113 g), her waistline had decreased by about 1.5 - 2 inches (3.8-5.1 cm), and her appetite had diminished. She continued taking CLA at the same dose level for three more
10 weeks during which time her body weight and waistline remained stabilized.

 It also will be readily apparent to those skilled in the art that a number of modifications or changes may be made without departing from the spirit and scope of the present
15 invention. Therefore, the invention is only to be limited by the claims.

-9-

CLAIMS

1. A method of maintaining an existing level of body fat or body weight of a human desiring to maintain that level comprises administering to said human a safe and effective amount of CLA to maintain said existing level.
- 5 2. A method of Claim 1 in which the CLA is administered in a food containing added CLA.
3. A method of Claim 1 in which the CLA is 9,11-octadecadienoic acid.
4. A method of Claim 1 in which the CLA is 10,12-
10 octadienoic acid.
5. A method of Claim 1 in which the CLA is in the form of an ester of a conjugated linoleic acid.
6. A method of Claim 1 in which the CLA is in the form of a non-toxic salt of a conjugated linoleic acid.
- 15 7. A method of Claim 1 in which the amount of CLA administered is equal to about 100 mg to about 20,000 mg. per day of the free conjugated linoleic acid.

INTERNATIONAL SEARCH REPORT

Int. Application No.
PCT/US 97/04538

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K A23D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FASEB J., vol. 10, no. 3, 8 March 1996, page A560 XP002034492 PARIZA ET AL.: "Conjugated linoleic acid (cla) reduces body fat" see abstract nr 3227	1,2
E	EP 0 779 033 A (UNILEVER) 18 June 1997 see page 2 lines 20-22, lines 35-40 see page 5, line 43 - line 45 see claim 3	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

4 July 1997

Date of mailing of the international search report

2 1. 07. 97

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Gac, G

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/04538

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BIOCHEM. BIOPHYS. RES. COMMUN., vol. 198, no. 3, 15 February 1994, pages 1107-1112, XP000567057 MILLER ET AL.: "Feeding Conjugated linoleic acid to animals partially overcomes catabolic responses due to endotoxin injection" see the whole document ---	1,2
Y	EP 0 579 901 A (WISCONSIN ALUMINI RESEARCH FOUNDATION) 26 January 1994 see the whole document ---	1,2
A	WO 96 06605 A (WISCONSIN ALUMINI RESEARCH FOUNDATION) 7 March 1996 see whole document, especially page 6 lines 1-4, page 7, lines 12-22, page 10 lines 5-16 ---	1-7
A	WO 94 16690 A (WISCONSIN ALUMINI RESEARCH FOUNDATION) 4 August 1994 see the whole document ---	1-7
A	JOURNAL OF NUTRITION, vol. 124, no. 5, 1 January 1994, pages 694-701, XP000574585 CHIN S F ET AL: "CONJUGATED LINOLEIC ACID (9,11- AND 10,12-OCTADECADIENOIC ACID) IS PRODUCED IN CONVENTIONAL BUT NOT GERM-FREE RATS FED LINOLEIC ACID" see page 696 left column second line, right column "results experiment 1" second paragraph see Figures 3A and 3B -----	1-4

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 97/04538

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-7
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. .ional Application No

PCT/US 97/04538

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 779033 A	18-06-97	AU 7175496 A	22-05-97
		CA 2190241 A	15-05-97
EP 579901 A	26-01-94	US 5430066 A	04-07-95
		DE 69301693 D	11-04-96
		DE 69301693 T	25-07-96
		US 5428072 A	27-06-95
		US 5504114 A	02-04-96
		US 5554646 A	10-09-96
WO 9606605 A	07-03-96	US 5554646 A	10-09-96
		EP 0731699 A	18-09-96
WO 9416690 A	04-08-94	US 5428072 A	27-06-95
		EP 0680318 A	08-11-95
		JP 8505775 T	25-06-96
		US 5504114 A	02-04-96
		US 5554646 A	10-09-96

